Table 5 Vertebral body dosimetric parameters for some common thoracic and abdominal tumors

Wang et al. (31),

2016

Gastric cancer,

n = 25

Adjuvant CRT (45 Gy/25f, chemotherapy based on capecitabine)

V₅ ≤ 90% for Grade 3 + leukopenia;

V₂₀ ≤ 78% for Grade 3 + neutropenia;

V₃₀ ≤ 60% for Grade 3 + thrombocytopenia

Zhang et al. (14),

2019

Esophageal cancer,

n = 53

Preoperative CRT (41.47 Gy, carboplatin-paclitaxel)

V₁₀ ≤ 49.1%, V₂₀ ≤ 46.5%, D_mean < 17.2 Gy for Grade 3 + leukopenia

Fabian et al. (29),

2019

Esophageal cancer,

n = 137

Neoadjuvant or definitive CRT (50.4–59.4 Gy, chemotherapy based on cisplatin/5-fluorouracil)

V₃₀ < 14% for Grade 3 + total HTs

Lee et al. (30),

2016

Esophageal cancer,

n = 41

Neoadjuvant CRT (41.4–48 Gy, chemotherapy based on cisplatin/ 5-fluorouracil)

V₂₀ < 70%, V₁₀ < 77%, D_mean < 25.9 Gy for Grade 3 + leukopenia

Barney et al. (28),

2017

Lung cancer,

n = 201

Definitive CRT (60–70 Gy, chemotherapy based on cisplatin)

V₅ ≤ 65%, V₁₀ ≤ 60%, V₂₀ ≤ 50%,

D_mean ≤ 23.5 Gy for Grade 3 + total HTs

Shaikh et al. (15),

2015

Pancreatic cancer,

n = 49

Definitive CRT (chemotherapy based on gemcitabine)

V₅ < 57.6% for Grade 2 + leukopenia;

D_max < 48.02 Gy for Grade 2 + neutropenia